Physician profile
Clova E Walters
NPI 1891836573
$2,002.90
in general payments reported to CMS, 2019-2025
14 companies · $717 in 2025
The $717 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.45 · 2020: $23.26 · 2021: $42.71 · 2022: $307 · 2023: $392 · 2024: $451 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $574.83 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $462.20 | 2022-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $202.24 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $162.75 | 2019-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $126.46 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.57 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $77.98 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $77.39 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $70.37 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $61.64 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $21.86 | 2023 | Ingrezza |
| Shire North American Group INC | $21.86 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.13 | 2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clova Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.